
FDA stops sale of generic versions of Ozempic and Wegovy: What it means for patients
The United States Food and Drug Administration (FDA) has stopped the sale of copycat versions of Ozempic and Wegovy, the Type 2 diabetes drugs used for weight loss.In 2022, the FDA announced there was a shortage of the brand-name medications, which allowed compounding pharmacies to make generic semaglutide, the main active ingredient in the weight-loss drugs.Compounding pharmacies create custom medications through mixing varying ingredients and dosages to better fit a patient’s needs. Traditiona...